| pubmed-article:9484820 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C1517927 | lld:lifeskim |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C1521733 | lld:lifeskim |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C0005510 | lld:lifeskim |
| pubmed-article:9484820 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:9484820 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9484820 | pubmed:dateCreated | 1998-3-5 | lld:pubmed |
| pubmed-article:9484820 | pubmed:abstractText | Forty-two patients with clinical stage IIIA or IIIB breast cancer were treated with neoadjuvant chemotherapy followed by mastectomy and radiotherapy. The median follow-up was 32 months (range 10-72 months) and the median time to progression was 17 months (range 10-30 months). A multivariate analysis showed that a longer disease-free survival (DFS) was related to more chemotherapy cycles given (P = 0.003), a better pathological response to chemotherapy (P = 0.04) and fewer positive axillary lymph nodes (P = 0.05). A better overall survival (OS) was related to more chemotherapy cycles given (P = 0.03) and better pathological response to chemotherapy (P = 0.04). In patients with residual tumour after neoadjuvant chemotherapy, high levels of staining for Ki-67 was correlated with a worse DFS (P = 0.008). Other biological characteristics, including oestrogen receptor status, microvessel density (CD31 staining), P-glycoprotein (P-gp) staining and nuclear accumulation of p53, were not independent prognostic factors for either DFS or OS. If both P-gp and p53 were expressed, DFS and OS were worse in the uni- and multivariate analysis. The preliminary results of this phase II study suggest that coexpression of P-gp/p53 and a high level of staining for Ki-67 after chemotherapy are associated with a worse prognosis, and that prolonged neoadjuvant chemotherapy and the attainment of a pathological complete remission are important factors in determining outcome for patients with this disease. | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9484820 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9484820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9484820 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9484820 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9484820 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:9484820 | pubmed:author | pubmed-author:LongM JMJ | lld:pubmed |
| pubmed-article:9484820 | pubmed:author | pubmed-author:PinedoH MHM | lld:pubmed |
| pubmed-article:9484820 | pubmed:author | pubmed-author:van DiestP... | lld:pubmed |
| pubmed-article:9484820 | pubmed:author | pubmed-author:GiacconeGG | lld:pubmed |
| pubmed-article:9484820 | pubmed:author | pubmed-author:WagstaffJJ | lld:pubmed |
| pubmed-article:9484820 | pubmed:author | pubmed-author:HoekmanKK | lld:pubmed |
| pubmed-article:9484820 | pubmed:author | pubmed-author:HonkoopA HAH | lld:pubmed |
| pubmed-article:9484820 | pubmed:author | pubmed-author:de JongJ SJS | lld:pubmed |
| pubmed-article:9484820 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9484820 | pubmed:volume | 77 | lld:pubmed |
| pubmed-article:9484820 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9484820 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9484820 | pubmed:pagination | 621-6 | lld:pubmed |
| pubmed-article:9484820 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:meshHeading | pubmed-meshheading:9484820-... | lld:pubmed |
| pubmed-article:9484820 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9484820 | pubmed:articleTitle | Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. | lld:pubmed |
| pubmed-article:9484820 | pubmed:affiliation | Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:9484820 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9484820 | lld:pubmed |
